Clinical trials in Capelle Aan Den Ijssel – page 5

1 543 clinical trials in Capelle Aan Den Ijssel, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Capelle Aan Den Ijssel at a glance

1 543

clinical trials

Research sites1

Quick filters

1 543 trials in Capelle Aan Den Ijssel

Open in trial search

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Siltuximab
Sponsor:Amgen Inc.

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:PIPE-791
Sponsor:Contineum Therapeutics Inc.

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Cervix carcinoma

Recruiting

Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

Registered drugNo placebo

Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Universitair Medisch Centrum Groningen

Contact Research Centre

Waldenstrom's macroglobulinaemia+2

Recruiting

A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.

InvestigationalNo placebo

A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Colorectal cancer metastatic+1

Recruiting

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Delcath Systems Inc.

Contact Research Centre

Study of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin

Registered drugNo placebo

Study of drug combination therapy for patients with lymph node-positive esophageal and esophagogastric junction cancer using carboplatin, paclitaxel, fluorouracil, folinic acid, docetaxel and oxaliplatin

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Pancreatic carcinoma

Recruiting

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Hydrocortisone
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Malignant melanoma

Recruiting

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Registered drugNo placebo

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Immatics US Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Capelle Aan Den Ijssel

What the registry says about research in the country

01 Oncology - Colorectal Studies

Multiple innovative trials focusing on colorectal cancer treatment strategies, including research on liver metastases management and chemotherapy optimization for older patients.

Hepatic arterial infusion therapy
Dose-adjusted chemotherapy protocols
Post-surgical treatment approaches

Advanced research exploring both surgical and medical interventions for improved patient outcomes.

02 Hematology & Breast Cancer

Groundbreaking studies in multiple myeloma treatment protocols and innovative approaches for hormone receptor-positive breast cancer management.

Treatment-free interval assessment
CDK 4/6 inhibition strategies
Endocrine therapy optimization

Focus on developing personalized treatment strategies for better long-term outcomes.

03 Inflammatory & Autoimmune Conditions

Comprehensive research on rheumatoid arthritis management, investigating novel treatment timing and personalized therapeutic approaches.

Chronotherapy effectiveness
Tailored management protocols
Cost-effectiveness analysis

Emphasis on patient-centered outcomes and treatment optimization.

Back to the Netherlands All countries